665 related articles for article (PubMed ID: 28332433)
41. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
42. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
[TBL] [Abstract][Full Text] [Related]
43. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
44. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
[TBL] [Abstract][Full Text] [Related]
45. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
Kiura K; Imamura F; Kagamu H; Matsumoto S; Hida T; Nakagawa K; Satouchi M; Okamoto I; Takenoyama M; Fujisaka Y; Kurata T; Ito M; Tokushige K; Hatano B; Nishio M
Jpn J Clin Oncol; 2018 Apr; 48(4):367-375. PubMed ID: 29474558
[TBL] [Abstract][Full Text] [Related]
46. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI
Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215
[TBL] [Abstract][Full Text] [Related]
47. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
Hida T; Satouchi M; Nakagawa K; Seto T; Matsumoto S; Kiura K; Nokihara H; Murakami H; Tokushige K; Hatano B; Nishio M
Jpn J Clin Oncol; 2017 Jul; 47(7):618-624. PubMed ID: 28369553
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
49. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
50. Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India.
Gupta D; Gupta N; Singh N; Prinja S
JCO Glob Oncol; 2024 Feb; 10():e2300260. PubMed ID: 38359374
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
52. Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China.
Peng Y; Ma F; Tan C; Wan X; Yi L; Peng L; Zeng X
Adv Ther; 2019 Nov; 36(11):3047-3058. PubMed ID: 31576479
[TBL] [Abstract][Full Text] [Related]
53. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
Gainor JF; Tan DS; De Pas T; Solomon BJ; Ahmad A; Lazzari C; de Marinis F; Spitaleri G; Schultz K; Friboulet L; Yeap BY; Engelman JA; Shaw AT
Clin Cancer Res; 2015 Jun; 21(12):2745-52. PubMed ID: 25724526
[TBL] [Abstract][Full Text] [Related]
54. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
Hida T; Nakagawa K; Seto T; Satouchi M; Nishio M; Hotta K; Takahashi T; Ohe Y; Takeda K; Tatsuno M; Asakawa T; Shimada T; Tanaka T; Tamura T
Cancer Sci; 2016 Nov; 107(11):1642-1646. PubMed ID: 27566263
[TBL] [Abstract][Full Text] [Related]
55. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
56. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
57. Optimal management of ALK-positive NSCLC progressing on crizotinib.
Metro G; Tazza M; Matocci R; Chiari R; Crinò L
Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
[TBL] [Abstract][Full Text] [Related]
58. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
59. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
60. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
